EUVIMEDEUVIMED entdecken
Crossref

“Time out for an hour, every day, my whole life”: understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI)

Jennifer L Butcher, Christopher Siracusa, Hannah Grabowski, Dana Yablon, Benjamin Ertman, Emma McWilliams, Tia Woo, Robin S Everhart, Jill Maggs, Michelle Prickett, Alex H Gifford, Nicole Mayer-Hamblett und 3 weitere

Journal of Cystic Fibrosis · 2025-11 · 24 (6) · 1130-1140

DOI: 10.1016/j.jcf.2025.07.014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-11. Verfasst von Jennifer L Butcher und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Psychology, CS Mott Children's Hospital, University of Michigan, 1540 East Hospital Drive, D2209 Medi…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Reducing treatment burden is a priority within the CF community. Improved outcomes for many people with CF (PWCF) following treatment with Elexacaftor/Tezacaftor/Ivacaftor (ETI) have led to considering whether daily CF regimens can be reduced. It is important to understand perceptions of PWCF when making decisions about care changes. We investigated how PWCF conceptualize treatment burden, including the types of burdens experienced, how burden has changed with ETI therapy, and how burden impacts treatment-related decision-making. METHODS: The Qualitative Understanding of Experiences with the SIMPLIFY Trial (QUEST) study recruited PWCF aged 14+ prescribed ETI and caregivers of teenagers for interviews following completion of the SIMPLIFY treatment discontinuation trial. Two semi-structured interviews were conducted, recorded, and transcribed. Treatment burden language was identified, coded, and thematically analyzed without prior hypotheses. RESULTS: 68 adults, 23 teenagers, and 23 caregivers participated in at least one interview. Treatment burden codes were identified and organized into 3 themes: 1) Defining Treatment Burden (time, organizational, social-emotional domains), 2) How Treatment Burden has Changed with ETI (increased, decreased), and 3) Strategies to Decrease Treatment Burden (combining treatments, skipping treatments, communicating with care team). CONCLUSION: Definitions of CF treatment burden are expansive and personalized. Interventions to reduce treatment burden should be individualized without assuming burden is perceived, or how each individual views and manages burdens. Personalized definitions of treatment burden will allow for tailored assessment and intervention strategies that match the needs of the individual.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesBenzodioxolesCost of IllnessPyridinesIndolesPyrazolesHumansFemaleMaleAdultDrug CombinationsAdolescentQualitative ResearchChloride Channel AgonistsCaregiversMiddle AgedYoung AdultQuinolines

Stichwörter der Autor:innen

Cystic fibrosisModulatorQualitativeTreatment burden

Substanzen

AminophenolsDrug CombinationsQuinolonesBenzodioxolesChloride Channel AgonistsPyridinesIndoleselexacaftor, ivacaftor, tezacaftor drug combinationPyrazolesQuinolines

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Pediatric Psychology, CS Mott Children's Hospital, University of Michigan, 1540 East Hospital Drive, D2209 Medical Professional Building, Ann Arbor, MI, 48109 USA. Electronic addres…
  • Division of Pulmonary Medicine, Cincinnati Children's Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Ave, Cincinnati, OH 45229 USA. Electronic ad…
  • Division of Pulmonary Medicine, Boston Children's Hospital, 333 Longwood Avenue, Boston, MA, 02115 USA. Electronic address: hannah.grabowski@childrens.harvard.edu.
  • Department of Medicine, Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, 5501 Hopkins Bayview Circle, Baltimore, MD, 21218 USA. Electronic address: dyablon2@jhmi.edu.
  • Division of Pulmonary Medicine, Boston Children's Hospital, 333 Longwood Avenue, Boston, MA, 02115 USA.
  • Division of Pulmonary Medicine, Boston Children's Hospital, 333 Longwood Avenue, Boston, MA, 02115 USA. Electronic address: emma.mcwilliams@childrens.harvard.edu.

Förderung

  • Cystic Fibrosis Foundation

Zitieren

APA

Butcher, J. L., Siracusa, C., Grabowski, H., Yablon, D., Ertman, B., McWilliams, E., Woo, T., Everhart, R. S., Maggs, J., Prickett, M., Gifford, A. H., Mayer-Hamblett, N., Nichols, D. P., Riekert, K. A., & Sawicki, G. S. (2025). “Time out for an hour, every day, my whole life”: understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI). Journal of Cystic Fibrosis, 24(6), 1130-1140. https://doi.org/10.1016/j.jcf.2025.07.014

Vancouver

Butcher JL, Siracusa C, Grabowski H, Yablon D, Ertman B, McWilliams E, et al. “Time out for an hour, every day, my whole life”: understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI). Journal of Cystic Fibrosis. 2025;24(6):1130-1140. doi:10.1016/j.jcf.2025.07.014

BibTeX
@article{Butcher2025,
  author = {Butcher, Jennifer L and Siracusa, Christopher and Grabowski, Hannah and Yablon, Dana and Ertman, Benjamin and McWilliams, Emma and Woo, Tia and Everhart, Robin S and Maggs, Jill and Prickett, Michelle and Gifford, Alex H and Mayer-Hamblett, Nicole and Nichols, David P and Riekert, Kristin A and Sawicki, Gregory S},
  title = {“Time out for an hour, every day, my whole life”: understanding treatment burden in cystic fibrosis in the era of Elexacaftor/Tezacaftor/Ivacaftor (ETI)},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {6},
  pages = {1130--1140},
  doi = {10.1016/j.jcf.2025.07.014}
}
Kostenlos starten →